This podcast was made possible by CIUT-FM 89.5, University of Toronto Community Radio. For more content, visit https://ciut.fm/

Join us for this comprehensive masterclass episode as we explore the fascinating world of K562 cells with Dr. Tom Karagiannis, who has worked with these remarkable cells for almost three decades. From his first encounter with them as a young researcher in 1996 during the exciting era of targeted therapy development, Dr. Karagiannis shares both the scientific breakthroughs and practical realities of working with these "weeds" of the lab.

📖 Video Chapters:

0:00 - The 1917 Origin Story: A Woman's Legacy

2:40 - Interview Begins: Dr. Tom Karagiannis on K562 Basics

5:42 - The 1990s Gleevec Revolution: Why K562 Cells Became Essential

7:10 - The Lozio Discovery: From Patient to Immortal Cell Line

8:48 - What Makes K562 Cells Special: Continuous Growth vs Normal Cells

10:36 - Cell Culture Evolution: From Glass Pipettes to Modern Labs

12:18 - Historical Context: HeLa Cells to Cancer Virus Research

14:26 - The Philadelphia Chromosome: Understanding the Genetic Driver

17:06 - Gleevec Revolution: The First Targeted Cancer Therapy

19:48 - K562 Cell Genetics: The Near-Triploid Puzzle

21:00 - Cell Differentiation: Research Applications and Advantages

24:08 - Transferrin Receptor Research: Dr. Tom's Early Work

28:37 - K562 Cells as "Weeds": Why They're So Easy to Grow

33:08 - Evolution of Cancer Research: From Targeted Therapy to CAR-T

35:42 - Personal Research Stories: Genetic Discoveries and Insights

36:03 - Genetic Discoveries: Novel Chromosomes and Cellular Evolution

42:27 - Drug Resistance Studies: Creating Doxorubicin-Resistant Cell Lines

44:12 - Epigenetic Research: HDAC Inhibitors and Combination Therapies

49:16 - Combination Therapy Mechanisms: How HDAC Inhibitors Enhance Chemotherapy

50:40 - Drug Resistance Reality: Gleevec Limitations and Cancer Stem Cells

53:54 - K562's Continued Value: Why Genetic Drift Doesn't Diminish Research Utility

57:27 - PhD Advice